Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03289039
Title Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

estrogen-receptor positive breast cancer

Therapies

Neratinib

Fulvestrant + Neratinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.